目的 探讨甘露特钠联合加兰他敏治疗血管性痴呆的临床疗效。方法 选取2021年7月—2023年6月上海市宝山区罗店医院收治的血管性痴呆患者100例，随机分为对照组（50例）和治疗组（50例）。对照组患者iv氢溴酸加兰他敏注射液，2 mg/次，2次/d。在对照组的基础上，治疗组口服甘露特钠胶囊，3粒/次，2次/d；两组用药28 d。观察两组患者临床疗效，比较治疗前后两组患者症状缓解时间，日常生活功能量表（ADL）和简易精神状态量表（MMSE）评分，血清炎性因子超氧化物歧化酶（SOD）、脂蛋白相关磷脂酶A₂（Lp-PLA₂）、白细胞介素1β（IL-1β）和脑源性神经营养因子（BDNF）水平。结果 治疗后，治疗组总有效率88.00%，明显高于对照组（70.00%，P＜0.05）。治疗后，治疗组症状好转时间均明显早于对照组（P＜0.05）。治疗后，两组患者ADL评分明显降低，而MMSE评分明显升高（P＜0.05），且治疗组ADL和MMSE评分明显好于对照组（P＜0.05）。治疗后，两组患者血清炎性因子IL-1β和Lp-PLA₂水平明显降低，而SOD和BDNF水平明显升高（P＜0.05），且治疗组血清炎性因子水平明显好于对照组（P＜0.05）。结论 甘露特钠联合加兰他敏治疗血管性痴呆可显著缓解临床症状，并能有效降低机体炎性反应状态，日常生活能力有效增强。

Objective To explore the clinical effect of sodium oligomannate combined with galantamine in treatment of vascular dementia. Methods Patients (100 cases) with vascular dementia in Shanghai Baoshan Luodian Hospital from July 2021 to June 2023 were randomly divided into control (50 cases) and treatment (50 cases) group. Patients in the control group were iv administered with Galantamine Hydrobromide Injection, 2 mg/time, twice daily. Patients in the treatment group were po administered with Sodium Oligomannate Capsules on the basis of the control group, 3 grains/time, twice daily. Patients in two groups were treated for 28 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, the scores of ADL and MMSE, the levels of serum IL-1β, Lp-PLA₂, SOD and BDNF in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 88.00%, which was significantly higher than that of the control group (70.005%, P < 0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the ADL score in two groups was significantly decreased, while the MMSE score was significantly increased (P < 0.05), and the ADL and MMSE scores in the treatment group were significantly better than those of the control group (P < 0.05). After treatment, the levels of serum inflammatory factors IL-1β and Lp-PLA₂ were significantly decreased, while the levels of SOD and BDNF were significantly increased in two groups (P < 0.05), and the level of serum inflammatory factors in the treatment group were significantly better than that in the control group (P < 0.05). Conclusion The synergistic treatment of galantamine and sodium oligomannate can significantly alleviate clinical symptoms, which can effectively reduce the inflammatory response state, effectively enhance daily living ability.

R971